TY  - JOUR
AU  - Peñalver, Francisco-Javier
AU  - Márquez, José-Antonio
AU  - Durán, Soledad
AU  - Giraldo, Pilar
AU  - Martín, Alejandro
AU  - Montalbán, Carlos
AU  - Sancho, Juan-Manuel
AU  - Ramírez, María-José
AU  - Terol, María-José
AU  - Capote, Francisco-Javier
AU  - Gutiérrez, Antonio
AU  - Sánchez, Blanca
AU  - López, Andrés
AU  - Salar, Antonio
AU  - Rodríguez-Caravaca, Gil
AU  - Canales, Miguel
AU  - Caballero, María-Dolores
AU  - GELTAMO (The Spanish Lymphoma Cooperative Group)
PY  - 2019
DO  - 10.1002/cam4.2555
UR  - http://hdl.handle.net/10668/14572
T2  - Cancer medicine
AB  - Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. This phase II trial evaluated the efficacy and safety of response-adapted therapy with...
LA  - en
KW  - bendamustine
KW  - follicular lymphoma
KW  - immunochemotherapy
KW  - refractory
KW  - relapsed
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bendamustine Hydrochloride
KW  - Dexamethasone
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Immunotherapy
KW  - Lymphoma, Follicular
KW  - Male
KW  - Middle Aged
KW  - Mitoxantrone
KW  - Neoplasm Recurrence, Local
KW  - Progression-Free Survival
KW  - Rituximab
KW  - Salvage Therapy
TI  - Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
TY  - research article
VL  - 8
ER  -